文献速递银屑病与炎症性皮肤病

瑞莎珠单抗与富马酸酯直接比较:系统治疗初治中重度斑块状银屑病随机对照试验

Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
PubMed 文献 · Br J Dermatol · 2021-08-17

该研究为德国Ⅲ期随机、活性对照、开放标签、疗效评估设盲试验,将系统治疗初治的中重度斑块状银屑病患者1:1随机分配至皮下瑞莎珠单抗150mg(第0、4、16周)或口服富马酸酯(从每日30mg递增至每日720mg,第8-24周)。

要点

  • 富马酸酯组胃肠道疾病、潮红、淋巴细胞减少和头痛发生率更高。
  • 瑞莎珠单抗组报告1例需住院的严重感染(流感),两组均无恶性肿瘤、结核或机会性感染。

核心结论

  • 瑞莎珠单抗在系统治疗初治的中重度斑块状银屑病患者中优于富马酸酯,起效更早、疗效更高且持续,安全性更有利。

研究设计与样本

  • 德国开展的Ⅲ期随机、活性对照、开放标签、疗效评估设盲试验,患者1:1随机至瑞莎珠单抗(n=60)或富马酸酯(n=60)。
  • 入组患者为成人、系统治疗初治且适合系统治疗、慢性中重度斑块状银屑病,研究前14天内及研究期间不允许光疗。

主要发现

  • 富马酸酯组胃肠道疾病、潮红、淋巴细胞减少和头痛发生率更高。
  • 瑞莎珠单抗组1例报告严重感染(流感,需住院);两组均无恶性肿瘤、结核或机会性感染。

临床怎么用

  • 对于系统治疗初治的中重度斑块状银屑病,瑞莎珠单抗可作为优于富马酸酯的一线系统治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fumaric acid esters (FAEs; Fumaderm® ) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi® ) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. OBJECTIVES: To compare risankizumab treatment to FAEs in patients with psoriasis. METHODS: This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8-24). Enrolled patients were adults naïve to and candidates for systemic therapy, with chronic moderate-to-severe plaque psoriasis. Phototherapy was not allowed within 14 days before or during the study. RESULTS: Key efficacy endpoints were met at week 24 for risankizumab (n = 60) vs. FAEs (n = 60) (P < 0·001): achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI; primary endpoint 83·3% vs. 10·0%), ≥ 100% improvement in PASI (50·0% vs. 5·0%), ≥ 75% improvement in PASI (98·3% vs. 33·3%), ≥ 50% improvement in PASI (100% vs. 53·3%) and a Static Physician's Global Assessment of clear/almost clear (93·3% vs. 38·3%). The rates of gastrointestinal disorders, flushing, lymphopenia and headache were higher in the FAE group. One patient receiving risankizumab reported a serious infection (influenza, which required hospitalization). There were no malignancies, tuberculosis or opportunistic infections in either treatment arm. CONCLUSIONS: Risankizumab was found to be superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favourable safety results, which is consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thaçi D, Eyerich K, Pinter A, et al. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2021. PMID: 33991341. doi:10.1111/bjd.20481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。